Pacific Biosciences Of California (PACB) Cash from Investing Activities (2010 - 2026)

Pacific Biosciences Of California has reported Cash from Investing Activities for 17 years, with the latest figure at $35.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities fell 20.73% year-over-year to $35.9 million; the trailing twelve-month figure through Mar 2026 stood at $106.1 million (down 47.84% YoY), and the FY2025 full-year result was $115.4 million, down 6.9% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $35.9 million, up from $26.0 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $242.3 million in Q3 2023, with the low at -$98.6 million in Q2 2023.
• Average Cash from Investing Activities over 5 years is $23.3 million, with a median of $26.0 million recorded in 2025.
• Year-over-year, Cash from Investing Activities surged 414.72% in 2022 and slumped 272.53% in 2023.
• Tracing PACB's Cash from Investing Activities over 5 years: stood at $80.4 million in 2022, then tumbled by 182.8% to -$66.6 million in 2023, then jumped by 187.48% to $58.2 million in 2024, then tumbled by 55.31% to $26.0 million in 2025, then soared by 37.77% to $35.9 million in 2026.
• The last three Cash from Investing Activities figures came in at $35.9 million (Q1 2026), $26.0 million (Q4 2025), and $18.9 million (Q3 2025), per Business Quant data.

Peer Comparison